SCHEMBL10243497

SCHEMBL10243497

CCN(CCNC(=O)OC)[C@@H](C)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 1/20 0.43
CNR1 P21554 2/20 0.41
CNR2 P34972 2/20 0.41
MTNR1A P48039 3/20 0.41
MTNR1B P49286 3/20 0.41
PGR P06401 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
KCNH2 Q12809 1/20 0.41
OPRD1 P41143 1/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CASR P41180 1/20 0.40
ALDH1A1 P00352 2/20 0.39
CYP3A4 P08684 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243510 0.88 ALOX5 (0.40) CNR1CNR2LMNAALDH1A1SMN1; SMN2
SCHEMBL10244037 0.86 CYP1A2 (0.46) CNR1CNR2MTNR1AMTNR1BHPGD
SCHEMBL10244695 0.86 SMN1; SMN2 (0.41) LMNACYP1A2CYP2D6ALDH1A1CYP3A4
SCHEMBL10243433 0.86 MAPT (0.43) CNR1MTNR1AMTNR1BCYP2D6SMN1; SMN2
SCHEMBL10243491 0.86 MEN1 (0.45) CNR1CYP1A2ALDH1A1SMN1; SMN2ALOX5
SCHEMBL10244079 0.86 ALDH1A1 (0.40) HPGDLMNAALDH1A1SMN1; SMN2
SCHEMBL10243623 0.86 HPGD (0.40) MTNR1AMTNR1BHPGDLMNACYP2D6
SCHEMBL10243525 0.86 ALOX5 (0.54) SMN1; SMN2ALOX5
SCHEMBL10244077 0.86 CYP2C19 (0.42) HPGDCYP2D6ALDH1A1CYP3A4
SCHEMBL10243821 0.86 OPRK1 (0.46) SLC22A1MTNR1AMTNR1BADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 SLC22A1 1994/4885CNR1 4356/4885CNR2 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.